Seeking Alpha
28 May 2026, 17:35 UTC · 2h ago
Source · https://seekingalpha.com/article/4909741-tg-therapeutics-strong-buy-amid-briumvi-expansion-win-and-boosted-2026-outlook
Read source
Search tags
Story key points
3 claims · impact-rated
TG Therapeutics raised 2026 BRIUMVI sales guidance to $885–$900 million. — Upward revisions to long-term revenue guidance directly increase valuation models and signal strong commercial scalability.
+0.80The Phase 3 ENHANCE trial was successful for single 600 mg IV BRIUMVI dosing. — Clinical success enables label expansion, opening new patient populations and increasing the drug's competitive moat.
+0.60BRIUMVI achieved 63% year-over-year sales growth in Q1. — Strong current growth validates market adoption and provides a foundation for future guidance.
+0.40Ticker attribution
Model heads
The company is rated as a 'Strong Buy' with robust revenue growth and successful Phase 3 trial results.
No ticker relationship head found.
Impact vectors
8 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
